Arvinas stock price target raised to $14 from $10 at BTIG on KRASG12D degrader potential
PositiveFinancial Markets

Arvinas has received a boost in its stock price target, now set at $14, up from $10, thanks to a positive assessment from BTIG regarding the potential of its KRASG12D degrader. This increase reflects growing confidence in the company's innovative approach to cancer treatment, which could significantly impact the market and provide new hope for patients. Investors are likely to view this as a strong signal of Arvinas' future prospects.
— Curated by the World Pulse Now AI Editorial System





